Conjoint Associate Professor Jarad Martin

Conjoint Associate Professor Jarad Martin

Conjoint Associate Professor

School of Medicine and Public Health

Career Summary

Biography

Conjoint Associate Professor Jarad Martin (DMEd, FRANZCR, GAustMS, MB ChB, BSc) is the Director of Research (Department of Radiation Oncology) and Radiation Oncologist at the Calvary Mater Newcastle, and Visiting Medical Officer at Genesis Cancer Care, Lake Macquarie Private Hospital.

With strong research interests in the areas of gastrointestinal and genitourinary oncology, A/Prof Martin has attracted over $4.5 million in competitive grant funding and has over 50 peer-reviewed publications to date. He is also Senior author on the Australasian guidelines for prostate cancer radiotherapy.

A/Prof Martin's professional leadership roles include: Faculty of Radiation Oncology; Chairperson Research Committee, Faculty of Radiation Oncology, Royal Australian and New Zealand College of Radiologists; Australia New Zealand Urological and Prostate Cancer Trials Group Scientific Advisory Committee; Trans-Tasman Radiation Oncology Group (TROG) Clinical Liason Leader; and Deputy Chairperson, Hunter Cancer Research Alliance (HCRA) Implementation Science Flagship Committee.


Qualifications

  • Doctor of Medicine, University of Queensland

Keywords

  • Diagnostics
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Radiation Oncology
  • Screening
  • Therapy and Treatment

Fields of Research

Code Description Percentage
111208 Radiation Therapy 50
029903 Medical Physics 50

Professional Experience

Professional appointment

Dates Title Organisation / Department
1/01/2012 -  Director of Research (Department of Radiation Oncology), Radiation Oncologist Calvary Mater Newcastle
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (37 outputs)

Year Citation Altmetrics Link
2015 Loh J, Baker K, Sridharan S, Greer P, Wratten C, Capp A, et al., 'Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?', RADIATION ONCOLOGY, 10 (2015) [C1]
DOI 10.1186/s13014-015-0347-2
Co-authors Peter Greer
2015 Dowling JA, Sun J, Pichler P, Rivest-Hénault D, Ghose S, Richardson H, et al., 'Automatic substitute computed tomography generation and contouring for magnetic resonance imaging (MRI)-alone external beam radiation therapy from standard MRI sequences', International Journal of Radiation Oncology Biology Physics, 93 1144-1153 (2015) [C1]

Crown Copyright © 2015 Published by Elsevier Inc. All rights reserved. Purpose To validate automatic substitute computed tomography CT (sCT) scans generated from standard T2-weig... [more]

Crown Copyright © 2015 Published by Elsevier Inc. All rights reserved. Purpose To validate automatic substitute computed tomography CT (sCT) scans generated from standard T2-weighted (T2w) magnetic resonance (MR) pelvic scans for MR-Sim prostate treatment planning. Patients and Methods A Siemens Skyra 3T MR imaging (MRI) scanner with laser bridge, flat couch, and pelvic coil mounts was used to scan 39 patients scheduled for external beam radiation therapy for localized prostate cancer. For sCT generation a whole-pelvis MRI scan (1.6 mm 3-dimensional isotropic T2w SPACE [Sampling Perfection with Application optimized Contrasts using different flip angle Evolution] sequence) was acquired. Three additional small field of view scans were acquired: T2w, T2*w, and T1w flip angle 80° for gold fiducials. Patients received a routine planning CT scan. Manual contouring of the prostate, rectum, bladder, and bones was performed independently on the CT and MR scans. Three experienced observers contoured each organ on MRI, allowing interobserver quantification. To generate a training database, each patient CT scan was coregistered to their whole-pelvis T2w using symmetric rigid registration and structure-guided deformable registration. A new multi-atlas local weighted voting method was used to generate automatic contours and sCT results. Results The mean error in Hounsfield units between the sCT and corresponding patient CT (within the body contour) was 0.6 ± 14.7 (mean ± 1 SD), with a mean absolute error of 40.5 ± 8.2 Hounsfield units. Automatic contouring results were very close to the expert interobserver level (Dice similarity coefficient): prostate 0.80 ± 0.08, bladder 0.86 ± 0.12, rectum 0.84 ± 0.06, bones 0.91 ± 0.03, and body 1.00 ± 0.003. The change in monitor units between the sCT-based plans relative to the gold standard CT plan for the same dose prescription was found to be 0.3% ± 0.8%. The 3-dimensional ¿ pass rate was 1.00 ± 0.00 (2 mm/2%). Conclusions The MR-Sim setup and automatic sCT generation methods using standard MR sequences generates realistic contours and electron densities for prostate cancer radiation therapy dose planning and digitally reconstructed radiograph generation.

DOI 10.1016/j.ijrobp.2015.08.045
Co-authors Fred Menk, Peter Greer
2015 Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, Martin J, 'Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy.', BMC Cancer, 15 281 (2015) [C3]
DOI 10.1186/s12885-015-1244-7
Co-authors Peter Stanwell
2015 Sun J, Dowling JA, Pichler P, Parker J, Martin J, Stanwell P, et al., 'Investigation on the performance of dedicated radiotherapy positioning devices for MR scanning for prostate planning', Journal of Applied Clinical Medical Physics, 16 4-13 (2015)

The purpose of this study was to investigate performance of the couch and coil mounts designed for MR-simulation prostate scanning using data from ten volunteers. Volunteers were ... [more]

The purpose of this study was to investigate performance of the couch and coil mounts designed for MR-simulation prostate scanning using data from ten volunteers. Volunteers were scanned using the standard MR scanning protocol with the MR coil directly strapped on the external body and the volunteer lying on the original scanner table. They also were scanned using a MR-simulation table top and pelvic coil mounts. MR images from both setups were compared in terms of body contour variation and image quality effects within particular organs of interest. Six-field conformal plans were generated on the two images with assigned bulk density for dose calculation. With the MR-simulation devices, the anterior skin deformation was reduced by up to 1.7 cm. The hard tabletop minimizes the posterior body deformation which can be up to 2.3 cm on the standard table, depending on the weight of volunteer. The image signal-to-noise ratio reduced by 14% and 25% on large field of view (FOV) and small FOV images, respectively, after using the coil mount; the prostate volume contoured on two images showed difference of 1.05 ± 0.66 cm3. The external body deformation caused a mean dose reduction of 0.6 ± 0.3 Gy, while the coverage reduced by 22% ± 13% and 27% ± 6% in V98 and V100, respectively. A dedicated MR simulation setup for prostate radiotherapy is essential to ensure the agreement between planning anatomy and treatment anatomy. The image signal was reduced after applying the coil mount, but no significant effect was found on prostate contouring.

DOI 10.1120/jacmp.v16i2.4848
Co-authors Fred Menk, Peter Greer, Peter Stanwell
2015 Sun J, Dowling J, Pichler P, Menk F, Rivest-Henault D, Lambert J, et al., 'MRI simulation: End-to-end testing for prostate radiation therapy using geometric pelvic MRI phantoms', Physics in Medicine and Biology, 60 3097-3109 (2015) [C1]

© 2015 Institute of Physics and Engineering in Medicine. To clinically implement MRI simulation or MRI-alone treatment planning requires comprehensive end-to-end testing to ensur... [more]

© 2015 Institute of Physics and Engineering in Medicine. To clinically implement MRI simulation or MRI-alone treatment planning requires comprehensive end-to-end testing to ensure an accurate process. The purpose of this study was to design and build a geometric phantom simulating a human male pelvis that is suitable for both CT and MRI scanning and use it to test geometric and dosimetric aspects of MRI simulation including treatment planning and digitally reconstructed radiograph (DRR) generation. A liquid filled pelvic shaped phantom with simulated pelvic organs was scanned in a 3T MRI simulator with dedicated radiotherapy couch-top, laser bridge and pelvic coil mounts. A second phantom with the same external shape but with an internal distortion grid was used to quantify the distortion of the MR image. Both phantoms were also CT scanned as the gold-standard for both geometry and dosimetry. Deformable image registration was used to quantify the MR distortion. Dose comparison was made using a seven-field IMRT plan developed on the CT scan with the fluences copied to the MR image and recalculated using bulk electron densities. Without correction the maximum distortion of the MR compared with the CT scan was 7.5 mm across the pelvis, while this was reduced to 2.6 and 1.7 mm by the vendor's 2D and 3D correction algorithms, respectively. Within the locations of the internal organs of interest, the distortion was <1.5 and <1 mm with 2D and 3D correction algorithms, respectively. The dose at the prostate isocentre calculated on CT and MRI images differed by 0.01% (1.1 cGy). Positioning shifts were within 1 mm when setup was performed using MRI generated DRRs compared to setup using CT DRRs. The MRI pelvic phantom allows end-to-end testing of the MRI simulation workflow with comparison to the gold-standard CT based process. MRI simulation was found to be geometrically accurate with organ dimensions, dose distributions and DRR based setup within acceptable limits compared to CT.

DOI 10.1088/0031-9155/60/8/3097
Citations Scopus - 1
Co-authors Jim Denham, Peter Greer, Fred Menk
2014 Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, et al., 'Circulating tumor cell detection in high-risk non-metastatic prostate cancer', Journal of Cancer Research and Clinical Oncology, 140 2157-2162 (2014) [C1]

© 2014, Springer-Verlag Berlin Heidelberg. Results: The median age was 70¿years, median PSA was 14.1, and the median Gleason score was 9. The median 5-year risk of progression o... [more]

© 2014, Springer-Verlag Berlin Heidelberg. Results: The median age was 70¿years, median PSA was 14.1, and the median Gleason score was 9. The median 5-year risk of progression of disease using a validated nomogram was 39¿%. Five out of 36 patients (14¿%, 95¿% CI 5¿30¿%) had CTCs detected in their circulation. Four patients had only 1 CTC per 7.5¿mL of blood detected. One patient had 3 CTCs per 7.5¿mL of blood detected, which included a circulating tumor microemboli. Both on univariate analysis and multivariate analysis, there were no correlations found between CTC positivity and the classic prognostic factors including PSA, Gleason score, T-stage and age. Conclusion: This study demonstrates that patients with high-risk, non-metastatic prostate cancer present infrequently with small number of CTCs in peripheral blood. This finding is consistent with the limited literature available in this setting. Other CTC isolation and detection technologies with improved sensitivity and specificity may enable detection of CTCs with mesenchymal phenotypes, although none as yet have been validated for clinical use. Newer assays are emerging for detection of new putative biomarkers for prostate cancer. Correlation of disease control outcomes with CTC detection will be important. Purpose: The detection of circulating tumor cells (CTCs) provides important prognostic information in men with metastatic prostate cancer. We aim to determine the rate of detection of CTCs in patients with high-risk non-metastatic prostate cancer using the CellSearch® method. Method: Samples of peripheral blood (7.5¿mL) were drawn from 36 men with newly diagnosed high-risk non-metastatic prostate cancer, prior to any initiation of therapy and analyzed for CTCs using the CellSearch® method.

DOI 10.1007/s00432-014-1775-3
Citations Scopus - 7Web of Science - 4
2014 Lehman M, Sidhom M, Kneebone AB, Hayden AJ, Martin JM, Christie D, et al., 'FROGG high-risk prostate cancer workshop: Patterns of practice and literature review. Part II post-radical prostatectomy', Journal of Medical Imaging and Radiation Oncology, 58 392-400 (2014) [C1]

Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to undertake a pattern of practice survey dealing with issues encountered in the man... [more]

Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to undertake a pattern of practice survey dealing with issues encountered in the management of high-risk prostate cancer in the post-prostatectomy setting. Responses from practitioners revealed a lack of consensus regarding the optimal timing of radiation therapy the use of whole pelvic radiation therapy and the use of androgen deprivation therapy. A review of the literature outlining the current body of knowledge and the clinical studies that will inform future practice is presented. © 2013 The Royal Australian and New Zealand College of Radiologists.

DOI 10.1111/1754-9485.12139
Citations Scopus - 1
2014 Martin J, Nicholson G, Cowin G, Ilente C, Wong W, Kennedy D, 'Rapid determination of vertebral fat fraction over a large range of vertebral bodies', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 58 155-163 (2014)
DOI 10.1111/1754-9485.12143
Citations Scopus - 2Web of Science - 1
2014 Loh J, Davis ID, Martin JM, Siva S, 'Extracranial oligometastatic renal cell carcinoma: current management and future directions', FUTURE ONCOLOGY, 10 761-774 (2014) [C1]
DOI 10.2217/fon.14.40
Citations Scopus - 3Web of Science - 3
2014 Ratnayake G, Martin J, Plank A, Wong W, 'Incremental changes verses a technological quantum leap: The additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 58 503-510 (2014) [C1]
DOI 10.1111/1754-9485.12153
2014 Robson K, Alizart M, Martin J, Nagel R, 'Coeliac Patients Are Undiagnosed at Routine Upper Endoscopy', PLOS ONE, 9 (2014) [C1]
DOI 10.1371/journal.pone.0090552
Citations Web of Science - 1
2014 Lehman M, Hayden AJ, Martin JM, Christie D, Kneebone AB, Sidhom M, et al., 'FROGG high-risk prostate cancer workshop: Patterns of practice and literature review: Part I: Intact prostate', Journal of Medical Imaging and Radiation Oncology, 58 257-265 (2014) [C1]

Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to participate in a pattern-of-practice survey dealing with the management of intact... [more]

Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to participate in a pattern-of-practice survey dealing with the management of intact high-risk prostate cancer. Responses from 46 practitioners (representing 73% of all potential respondents) revealed that high-dose radiation therapy is the standard of care. However, there is variability in practice with regard to the methods used to achieve dose escalation, the use of whole-pelvic radiation therapy and the optimal duration of androgen deprivation therapy employed. A review of the literature outlining the current body of knowledge and the planned and ongoing studies in intact high-risk prostate cancer is presented. © 2013 The Authors. Journal of Medical Imaging and Radiation Oncology published by Wiley Publishing Asia Pty Ltd on behalf of Royal Australian and New Zealand College of Radiologists.

DOI 10.1111/1754-9485.12142
Citations Scopus - 3Web of Science - 3
2013 Healy B, Frantzis J, Murry R, Martin J, Plank A, Middleton M, et al., 'Results from a multicenter prostate IMRT dosimetry intercomparison for an OCOG-TROG clinical trial.', Medical physics, 40 071706 (2013)
DOI 10.1118/1.4808151
2013 Martin J, Frantzis J, Chung P, Langah I, Crain M, Cornes D, et al., 'Prostate radiotherapy clinical trial quality assurance: How real should real time review be? (A TROG-OCOG Intergroup Project)', RADIOTHERAPY AND ONCOLOGY, 107 333-338 (2013) [C1]
DOI 10.1016/j.radonc.2013.05.015
Citations Scopus - 3Web of Science - 2
2013 Grimison P, Houghton B, Chatfield M, Toner GC, Davis ID, Martin J, et al., 'Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage i testicular cancer', BJU International, 112 (2013) [C1]
DOI 10.1111/bju.12221
Citations Scopus - 6
2013 Trada Y, Plank A, Martin J, 'Defining a doseresponse relationship for prostate external beam radiotherapy', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 57 237-246 (2013) [C1]
DOI 10.1111/1754-9485.12008
Citations Scopus - 3Web of Science - 1
2012 Lin C, Tripcony L, Keller J, Poulsen M, Martin J, Jackson J, Dickie G, 'PERINEURAL INFILTRATION OF CUTANEOUS SQUAMOUS CELL CARCINOMA AND BASAL CELL CARCINOMA WITHOUT CLINICAL FEATURES', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82 334-340 (2012) [C1]
DOI 10.1016/j.ijrobp.2010.09.040
Citations Scopus - 14Web of Science - 11
2012 Khoo ELH, Schick K, Plank AW, Poulsen M, Wong WWG, Middleton M, Martin JM, 'PROSTATE CONTOURING VARIATION: CAN IT BE FIXED?', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82 1923-1929 (2012) [C1]
DOI 10.1016/j.ijrobp.2011.02.050
Citations Scopus - 10Web of Science - 9
2012 Gillett J, Ientile C, Hiscock J, Plank A, Martin JM, 'Complementary and Alternative Medicine Use in Radiotherapy: What Are Patients Using?', JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 18 1014-1020 (2012) [C1]
DOI 10.1089/acm.2011.0334
Citations Scopus - 9Web of Science - 11
2012 Hansen CJ, Kenny L, Lakhani SR, Ung O, Keller J, Tripcony L, et al., 'Tubular breast carcinoma: An argument against treatment de-escalation', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 56 116-122 (2012) [C1]
DOI 10.1111/j.1754-9485.2011.02330.x
Citations Scopus - 3Web of Science - 3
2011 Martin JM, Brett R, Blyth J, Morrison S, Bryant D, Plank A, et al., 'Dosimetric effect of external beam planning preceding combined high-dose-rate brachytherapy of the prostate', BRACHYTHERAPY, 10 474-478 (2011) [C1]
DOI 10.1016/j.brachy.2010.10.003
Co-authors Michael Fay
2011 Martin JM, Supiot S, Berthold DR, 'Pharmacotherapeutic Management of Locally Advanced Prostate Cancer Current Status', DRUGS, 71 1019-1041 (2011) [C3]
Citations Scopus - 12Web of Science - 11
2011 Healy B, Frantzis J, Murry R, Martin J, Middleton M, Catton C, Kron T, 'Development of a dosimetry inter-comparison for IMRT as part of site credentialing for a TROG multi-centre clinical trial for prostate cancer.', Australasian physical & engineering sciences in medicine / supported by the Australasian College of Physical Scientists in Medicine and the Australasian Association of Physical Sciences in Medicine, 34 195-202 (2011) [C1]
DOI 10.1007/s13246-011-0063-7
2011 Middleton M, Frantzis J, Healy B, Jones M, Murry R, Kron T, et al., 'SUCCESSFUL IMPLEMENTATION OF IMAGE-GUIDED RADIATION THERAPY QUALITY ASSURANCE IN THE TRANS TASMAN RADIATION ONCOLOGY GROUP 08.01 PROFIT STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81 1576-1581 (2011) [C1]
DOI 10.1016/j.ijrobp.2010.09.017
Citations Scopus - 16Web of Science - 9
2010 Hayden AJ, Martin JM, Kneebone AB, Lehman M, Wiltshire KL, Skala M, et al., 'Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 54 513-525 (2010) [C3]
DOI 10.1111/j.1754-9485.2010.02214.x
Citations Scopus - 19Web of Science - 13
2010 Martin JM, Frantzis J, Eade T, Chung P, 'Clinician's guide to prostate IMRT plan assessment and optimisation', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 54 569-575 (2010) [C1]
DOI 10.1111/j.1754-9485.2010.02217.x
Citations Scopus - 7Web of Science - 6
2010 Poulsen M, Middleton M, McQuitty S, Ramsay J, Gogna K, Martin J, et al., 'Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility', Journal of Medical Imaging and Radiation Oncology, 54 368-374 (2010) [C1]

The aim was to compare a private Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility (QHF) in Brisbane. The comparison conce... [more]

The aim was to compare a private Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility (QHF) in Brisbane. The comparison concentrated on staffing, case mix and operational budgets, but was not able to look at changes in access to services. Data were collected from the two facilities from January 2008 to June 2008 inclusive. A number of factors were compared, including case mix, staffing levels, delay times for treatment, research, training and treatment costs. The case mix between the two areas was similar with curative treatments making up just over half the work load in both centres and two-thirds the work being made up of cancers of breast and prostate. Staffing levels were leaner in Toowoomba, especially in the areas of nursing, administration and trial coordinators. Research activity was slightly higher in Toowoomba. The average medicare cost per treatment course was similar in both centres ($5000 per course). Total costs of an average treatment including patient, State and Commonwealth costs, showed a 30% difference in costing favouring Toowoomba. This regional radiation oncology centre has provided state-of-the-art cancer care that is close to home for patients living in the Darling Downs region. Both public and private patients have been treated with modest costs to the patient and significant savings to QH. The case mix is similar to the QHF, and there has been significant activity in clinical research. A paperless working environment is one factor that has allowed staffing levels to be reduced. Ongoing support from Governments are required if private facilities are to participate in important ongoing staff training. © 2010 The Royal Australian and New Zealand College of Radiologists.

DOI 10.1111/j.1754-9485.2010.02166.x
2010 Martin JM, Gorayski P, Zwahlen D, Fay M, Keller J, Millar J, 'IS RADIOTHERAPY A GOOD ADJUVANT STRATEGY FOR MEN WITH A HISTORY OF CRYPTORCHISM AND STAGE I SEMINOMA?', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76 65-70 (2010) [C1]
DOI 10.1016/j.ijrobp.2009.01.027
Citations Scopus - 2Web of Science - 1
Co-authors Michael Fay
2009 Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, et al., 'Image guided dose escalated prostate radiotherapy: still room to improve', RADIATION ONCOLOGY, 4 (2009) [C1]
DOI 10.1186/1748-717X-4-50
Citations Scopus - 11Web of Science - 34
2009 Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, et al., 'Image guided dose escalated prostate radiotherapy: still room to improve (vol 4, pg 50, 2009)', RADIATION ONCOLOGY, 4 (2009) [C3]
DOI 10.1186/1748-717X-4-65
Citations Scopus - 30Web of Science - 2
2009 Jackson J, Dickie G, Poulsen M, Martin J, 'EXISTENCE OF MRI-NEGATIVE CLINICAL (LARGE NERVE) PERINEURAL SQUAMOUS CELL CARCINOMA SPREAD Reply', HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 31 1532-1533 (2009) [C3]
2008 Middleton M, See A, Rolfo A, Medwell S, Joon ML, Joon DL, et al., 'Intraprostatic fiducials for image guidance: Workflow implications in a single linac department', Radiography, 14 312-317 (2008) [C1]

Purpose: To assess the accuracy and implications on workflow of an online correction electronic portal imaging (EPI) protocol utilising bony anatomy in the online environment and ... [more]

Purpose: To assess the accuracy and implications on workflow of an online correction electronic portal imaging (EPI) protocol utilising bony anatomy in the online environment and an assessment of three implanted gold seed fiducial markers in the offline environment. This paper summarises an initial trial to establish the range of systematic and random errors present in patient set-up for both bony anatomy and fiducial markers, and to calculate optimal clinical target volume (CTV) to planning target volume (PTV) margins. The impact of the introduction of such a technique was also assessed in terms of impact on workflow and resource management in a single machine unit (SMU). Methods and materials: Pre treatment electronic portal images (EPIs) were acquired and bony anatomy was matched with CT derived digitally reconstructed radiographs (DRRs). Intervention in field placement was made if field placement fell outside the range of 4 mm on any of the orthogonal axes. In the offline environment the position of the implanted gold seed fiducials was aligned with that of the DRRs. An analysis of set-up error, total error and internal organ motion was then undertaken, with full statistical analysis of systematic and random errors. Results: Eleven patients completed treatment as specified, with 1006 EPIs available for analysis. Treatment times were in the order of 10.4 min. Set-up errors were in the order of 2.7 mm right-left, 2.4 mm sup-inf and 1.6 mm ant-pst. These were reduced to 1.2 mm, 0.7 mm and 0.9 mm respectively utilising an online correction protocol. However there was minimal impact on total error and internal organ motion. Using the data obtained in both the online and offline environments optimal CTV-PTV margins were calculated for correcting to bone, correcting to gold seed fiducials and also the possibility of EPI malfunction. Conclusions: Daily targeting of the prostate is both technically feasible and can be carried out in an efficient and accurate manner. An online correction protocol using gold seeds as the matching mechanism provides the ability to significantly reduce treatment margins for most prostate patients, and importantly does not impact on a busy clinical workflow. © 2007 The College of Radiographers.

DOI 10.1016/j.radi.2007.11.002
Citations Scopus - 6
2008 Zwahlen DR, Martin JM, Millar JL, Schneider U, 'Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70 853-858 (2008) [C1]
DOI 10.1016/j.ijrobp.2007.10.007
Citations Scopus - 33Web of Science - 29
2007 Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, et al., 'Phase II trial of hypofractionated image-guided intensitymodulated radiotherapy for localized prostate adenocarcinoma', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69 1084-1089 (2007)
DOI 10.1016/j.ijrobp.2007.04.049
Citations Scopus - 89Web of Science - 78
2004 Martin JM, Ryan G, Duchesne G, 'Clinical prioritisation for curative radiotherapy: a local waiting list initiative.', Clinical oncology (Royal College of Radiologists (Great Britain)), 16 299-306 (2004)
DOI 10.1016/j.clon.2003.12.008
2004 Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, et al., 'Paranasal sinus tumors: Peter MacCallum Cancer Institute experience.', Head & neck, 26 322-330 (2004)
DOI 10.1002/hed.10388
2004 Martin JM, Porceddu S, Weih L, Corry J, Peters LJ, 'Outcomes in sinonasal mucosal melanoma', ANZ JOURNAL OF SURGERY, 74 838-842 (2004)
DOI 10.1111/j.1445-1433.2004.03185.x
Citations Web of Science - 13
Show 34 more journal articles

Conference (3 outputs)

Year Citation Altmetrics Link
2011 Trada Y, Plank A, Martin JM, 'Establishing a Dose Response Relationship for the Treatment of Prostate Cancer With External Beam Radiotherapy: a Meta-analysis', EUROPEAN JOURNAL OF CANCER (2011) [E3]
2009 Jackson JE, Dickie GJ, Wiltshire KL, Keller J, Tripcony L, Poulsen MG, et al., 'RADIOTHERAPY FOR PERINEURAL INVASION IN CUTANEOUS HEAD AND NECK CARCINOMAS: TOWARD A RISK-ADAPTED TREATMENT APPROACH', HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2009) [E1]
DOI 10.1002/hed.20991
Citations Scopus - 19Web of Science - 15
2008 Gorayski P, Zwahlen D, Fay M, Millar J, Cattley T, Keller J, Martin JM, 'Should men with stage one testicular seminoma and a history of cryptorchism be offered adjuvant radiotherapy?', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008) [E3]
DOI 10.1016/j.ijrobp.2008.06.1149
Co-authors Michael Fay
Edit

Grants and Funding

Summary

Number of grants 19
Total funding $1,679,831

Click on a grant title below to expand the full details for that specific grant.


20151 grants / $20,000

Neurotrophic growth factors as biomarkers and therapeutic targets in prostate cancer$20,000

Funding body: Hunter Cancer Research Alliance

Funding body Hunter Cancer Research Alliance
Project Team
Scheme Biomarkers and Targeted Therapies Flagship Program: Pilot Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo
Type Of Funding Internal
Category INTE
UON N

20144 grants / $59,000

Prostate Cancer: A new protein for improving diagnosis, prognosis and treatment$20,000

Funding body: Hunter Medical Research Institute (HMRI)

Funding body Hunter Medical Research Institute (HMRI)
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Multiparametric MRI for Response Assessment of Anal Canal Squamous Cell Carcinoma$20,000

Funding body: Royal Australian and New Zealand College of Radiologists

Funding body Royal Australian and New Zealand College of Radiologists
Project Team
Scheme Project grant
Role Investigator
Funding Start 2014
Funding Finish 2015
GNo
Type Of Funding Not Known
Category UNKN
UON N

A prospective study of MRI based prostate treatment planning$19,000

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team
Scheme Jane Reid Harle Memorial Fund
Role Investigator
Funding Start 2014
Funding Finish 2015
GNo
Type Of Funding Not Known
Category UNKN
UON N

SPARK: Stereotactic Prostate Adaptive Radiotherapy utilising Kilovoltage intrafraction monitoring$0

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2015
GNo
Type Of Funding Not Known
Category UNKN
UON N

20131 grants / $105,771

Advanced Radiation Oncology Clinical Trials: A Remotely Accessible Solution for Treatment Plan Review$105,771

Funding body: Cancer Instititue NSW

Funding body Cancer Instititue NSW
Project Team
Scheme Research Equipment Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

20124 grants / $540,000

Enhancing Coordination of Complex Collaborative Clinical Trials in NSW: A TROG Initiative$300,000

Funding body: Cancer Instititue NSW

Funding body Cancer Instititue NSW
Project Team
Scheme Cooperative Clinical Trials
Role Lead
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

Safety and Quality IMRT Treatment Delivery Accuracy$200,000

Funding body: American Society for Therapeutic Radiation Oncology

Funding body American Society for Therapeutic Radiation Oncology
Project Team
Scheme Research Grant
Role Investigator
Funding Start 2012
Funding Finish 2013
GNo
Type Of Funding Not Known
Category UNKN
UON N

Multiparametric MRI for Response Assessment of Anal Canal Squamous Cell Carcinoma$20,000

Funding body: Hunter Translational Cancer Research Unit

Funding body Hunter Translational Cancer Research Unit
Project Team
Scheme Seed Funding
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Internal
Category INTE
UON N

Real Time Verification of Dynamic Radiotherapy$20,000

Funding body: Hunter Translational Cancer Research Unit

Funding body Hunter Translational Cancer Research Unit
Project Team
Scheme Seed Funding
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Internal
Category INTE
UON N

20112 grants / $158,800

Exploring Androgen Deprivation Therapy derived osteopaenia through MRI quantification of marrow, fat and bone composition$80,000

Funding body: Abbott Australasia Pty Ltd

Funding body Abbott Australasia Pty Ltd
Project Team
Scheme Research Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Gonadotrophin Releasing Hormone agonists and the metabolic syndrome – Pathophysiology and mitigation in a rat model$78,800

Funding body: Abbott Australasia Pty Ltd

Funding body Abbott Australasia Pty Ltd
Project Team
Scheme Research Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

20091 grants / $176,260

Monitoring tumour Movement during Radiotherapy by 4D Ultrasound Imaging$176,260

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2011
GNo
Type Of Funding Not Known
Category UNKN
UON N

20082 grants / $451,000

Phase III trial 'PROFIT: Prostate Fractionated Irradiation'$435,500

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team
Scheme Infrastructure support for clinical trials program
Role Lead
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

PROFIT$15,500

Funding body: Queensland Clinical Oncology Group

Funding body Queensland Clinical Oncology Group
Project Team
Scheme Research Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

20073 grants / $140,000

Phase III trial 'PROFIT: Prostate Fractionated Irradiation'$100,000

Funding body: Prostate Cancer Foundation of Australia

Funding body Prostate Cancer Foundation of Australia
Project Team
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Not Known
Category UNKN
UON N

Phase III trial 'PROFIT: Prostate Fractionated Irradiation'$20,000

Funding body: Trans-Tasman Radiation Oncology Group

Funding body Trans-Tasman Radiation Oncology Group
Project Team
Scheme Project grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Not Known
Category UNKN
UON N

FLT-PET for patients with Head and Neck Squamous Cell Carcinoma managed with chemoradiotherapy (CRT)$20,000

Funding body: Royal Brisbane and Women's Hospital

Funding body Royal Brisbane and Women's Hospital
Project Team
Scheme Project Grant & New Investigator Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Not Known
Category UNKN
UON N

20041 grants / $29,000

Phase II trial of whole abdominal radiotherapy for platinum resistant recurrent ovarian carcinoma$29,000

Funding body: Merck Medical School Grant

Funding body Merck Medical School Grant
Project Team
Scheme Merck Medical School Grant
Role Lead
Funding Start 2004
Funding Finish 2004
GNo
Type Of Funding Not Known
Category UNKN
UON N
Edit

Research Supervision

Number of supervisions

Completed0
Current2

Total current UON EFTSL

PhD0.45

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2013 PhD In Vivo Dosimetry and Intrafraction Motion During Prostate Radiotherapy
PhD (Physics), Faculty of Science and Information Technology, The University of Newcastle
Co-Supervisor
2013 PhD Anal Cancer and Multiparametric MRI
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 40
Canada 6
Switzerland 2
France 1
United Kingdom 1
More...
Edit

Conjoint Associate Professor Jarad Martin

Position

Conjoint Associate Professor
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email jarad.martin@newcastle.edu.au
Edit